AI-generated from publicly available materials.Big Picture Bio, a London-based biotech startup, has officially launched with €2.55 million in funding to develop AI-driven cancer therapies.
The funding consists of a €1.75 million pre-Seed round led by Kadmos Capital and Exceptional Ventures, complemented by €815k in non-dilutive support from Innovate UK. Founders Dr. Kerstin Papenfuss and Dr. Mark Hammond, both with extensive backgrounds in therapeutics and technology, aim to revolutionize drug development by using AI to predict the effectiveness of drug combinations in complex clinical trials.
Big Picture Bio has created a generative model that simulates interactions between tumors, immune cells, and surrounding tissues. This innovative approach allows for rapid computational analysis of potential drug combinations, which would be impractical to test through traditional lab experiments. Their model has already demonstrated predictive capabilities by accurately forecasting outcomes in clinical trials.
As the company transitions its AI-designed therapies from theoretical models to practical lab experiments, it seeks to redefine how cancer treatments are developed. By focusing on the dynamic nature of cancer, Big Picture Bio aims to create tailored drug combinations that are more likely to succeed in real-world patient scenarios, moving beyond conventional trial-and-error methods.